
Up to 19 different Chlamydia trachomatis (CT) serovars which are pathogenic predominantly for the urogenital tract and numerous CT variants have been identified. An increasing number of isolates are typed worldwide and provide a wealth of information on the epidemiology of CT infections, a sexually transmitted disease (STD) for which screening has been proposed. Recent studies have demonstrated an association between CT serovar G and squamous cell carcinoma. A possible shift in the serovar distribution over time in a region or country could reveal information on changes in the epidemiology of CT infections and could potentially have clinical implications.

We therefore determined the CT serovar distribution in a large STD population in Amsterdam in 2000–2 and compared it together with all published serovar distributions since 1986 in the Netherlands to assess if serovar distribution shifts over time occurred.

Of people attending the STD outpatient clinic in Amsterdam from 2000–2, those found CT positive (n = 407) by LGX (Abbott Laboratories, Chicago, IL, USA) were genotyped as described previously. This is the largest STD population typed to date in The Netherlands. The following serovar distribution was found: B = 1%; D = 12%; Da = 0.2%; D- = 1%; E = 33%; F = 23%; G = 4%; Ga = 9%; H = 8%; I = 6%; Ia = 1%; J = 3%; K = 2%.

Literature searches identified eight serovar distribution studies in the Netherlands, of which the first was performed in 1986. With the inclusion of the present study, 2204 serovars were available for analyses. In the serovar distributions comparison, we (1) did not distinguish between male and female participants, (2) did not distinguish between serovar distributions based on serotyping or genotyping techniques, (3) excluded serovar B/Ba because of the low numbers, (4) excluded double infections, (5) excluded variants, and (6) classified CT serovars in the three phylogenetically based serogroups: the B group (serovars D, Da, E), the intermediate serogroup (serovars F, G, Ga), and the C group (serovars I, Ia, J, Iv, and K).

Results are shown in figure 1. In general, no statistical significant serovar distribution trends in time were observed between 1986 and 2002 when all studies were taken together. Of the nine studies, 1 and 6 represent serovar distributions from STD populations in Rotterdam and show no significant changes in general or over time (mean: C group: 30%; Int group: 21%; B group: 49%). Studies 2, 3, 4, and 9 represent serovar distributions from STD populations in Amsterdam and show no significant changes (mean: C group: 20%; Int group: 31%; B group: 49%). Studies 5, 7, and 8 represent serovar distributions from mixed symptomatic and asymptomatic infected people (5 and 7) and asymptotically infected populations in Amsterdam. They show no significant changes in general, over time, or compared to the Amsterdam STD based serovar distribution (C group: 17%; Int group: 30%; B group: 53%).

However, when the two geographically derived serovar distributions were compared to each other, (1) serovar C was found more frequently in Rotterdam: 30 v 19% (p<0.0001; OR 1.8 (95% CI: 1.4 to 2.3)), the most prominent serovar difference was serovar K (10.6 v 3.2%, p<0.0001; OR 3.6 (95% CI 2.4 to 5.3)); (2) the intermediate serogroup was found less frequently in Rotterdam: 21 v 31% (p=0.0002; OR 1.6 (95% CI: 1.2 to 2.0)), the most prominent serovar difference was serovar F (15 v 22%, p=0.0018; OR 1.6 (95% CI: 1.2 to 2.1)), and serovogroup B was stable (49% v 50%).

In conclusion, no changes in serovar distribution differences were found over time in the Netherlands in general or within the two different geographic areas. However, the Rotterdam population differed significantly from the Amsterdam population in having a larger incidence of C group serovars and a lower incidence of the intermediate group serovars, albeit an identical B group serovar distribution. The findings could be the result of different ethnic compositions of the studied cohorts or other confounding factors between Rotterdam and Amsterdam, a subject that warrants further study.
Components are conducting Chlamydia trachomatis infections, database management, writing of the manuscript; CS responsible for the statistical analyses; JV and SM, technicians performing all chlamydia typing experiments (culture and PCR based RFLP typing) and sample database management; HSAF, in charge of the STD outpatient clinic in Amsterdam, responsible for the logistics of the sample collection. All chlamydia typing experiments were performed by highly sensitive PCR. J Clin Microbiol 1995;33:3114–7.


Correspondence to: Dr Nicola Low, Department of Sexual Health and HIV, University of Bristol, Canyng Hall, Whiteladies Road, Bristol BS8 2PR, UK

H S A Fennema
Sexual Transmitted Diseases Outpatient Clinic, Municipal Health Service, Amsterdam, Netherlands

A Souto, J H T Wagenvoort
Cluster Infectious Diseases, Department of HIV and STI Research, Municipal Health Service, Amsterdam, Netherlands

H S A Fennema
Sexual Transmitted Diseases Outpatient Clinic, Municipal Health Service, Amsterdam, Netherlands

R A Coutinho
Municipal Health Service, Amsterdam, Netherlands

A Salvador Peña, S A Morreá
Laboratory of Immunogenetics, Section Immunogenetics of Infectious Diseases, VU University Medical Center, Amsterdam, Netherlands

Address correspondence and reprint requests to: Joke Spooragaren, MD, Public Health Laboratory, Municipal Health Service, Amsterdam, Nieuwe Achtergracht 100, 1018 WT, Amsterdam, Netherlands; j.spooragaren@ggd.amsterdam.nl

Accepted for publication 5 August 2003

References


Comparison of the serological response to treatment of early syphilis in HIV positive versus HIV negative individuals

The effectiveness of treatment for syphilis is evaluated by demonstrating declining titres of the non-treponemal antibody tests—for example, the rapid plasma reagin (RPR). The serological response in HIV co-infected individuals has been the subject of debate, with some studies reporting a similar serological response 1 and others a delayed response in HIV positive patients. 7

A resurgence of infectious syphilis has occurred in Manchester, United Kingdom, in recent years. 8 From January 1999 to August 2002, 379 cases of early syphilis were
reported and 28% were HIV co-infected (CDSC North West, personal communication). North Manchester General Hospital (NMGH) houses one of the city’s three genitourinary medicine clinics and the regional infectious diseases unit, providing care for approximately 1000 HIV positive individuals. Our aim was to evaluate the serological response to treatment for early syphilis in HIV positive and negative individuals treated at NMGH. Between January 1999 and March 2002, 75 men (72 homosexual) and three women had been diagnosed with early syphilis. Of the 78, 40/75 men (72 homosexual) and three women were HIV positive. The RPR results 3, 6, and 12 months following treatment for early syphilis were collected by retrospective case note review. Exclusion criteria were syphilis re-infection during the study period (two patients), HIV status undetermined (six patients declined HIV testing), or lost to follow up (16 patients). Patients were divided into two groups—HIV positive and HIV negative individuals. From the sequential RPR results 3, 6, and 12 months following treatment the mean reduction in RPR titres in each group were calculated, and statistical comparison made between the two groups using the Student’s t test.

The results are shown in Table 1. We found no significant difference in the reduction of RPR titres in the year following treatment between the HIV positive and negative groups. Of the 31 HIV positive individuals in this study, 17 were taking highly active antiretroviral therapy at the time their syphilis was diagnosed. The average CD4 lymphocyte count in this group was 460×10^3 (range 33–1000) and viral load 83515 copies/ml (range <50–442 000).

Limitations of the study are that it was retrospective, patients in the HIV positive and negative groups were not matched individually for variables such as stage of syphilis or initial RPR titre, and the treatment regimens varied (at least 10 days intramuscular procaine penicillin or 14 days oral doxycycline, and HIV positive patients prolonged courses of treatment in accordance with the UK national guidelines for the treatment of early syphilis). No account was taken of the patient’s CD4 lymphocyte count, or whether they were receiving antiretroviral therapy. However, the cohort represents a diverse group of HIV positive individuals and we consider them representative of those generally encountered in clinical practice.

We demonstrated that in clinical practice the RPR remains a valid way of assessing the response to treatment of syphilis in those co-infected with HIV. Larger prospective studies, with cases and controls matched for variables such as the stage of syphilis at diagnosis, the initial RPR titre, and treatment regimens are required.

<table>
<thead>
<tr>
<th>No of patients</th>
<th>Mean drop in RPR</th>
<th>No of patients</th>
<th>Mean drop in RPR</th>
<th>No of patients</th>
<th>Mean drop in RPR</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 months HIV positive</td>
<td>31</td>
<td>1.71</td>
<td>20</td>
<td>2.20</td>
<td>12</td>
</tr>
<tr>
<td>3 months HIV negative</td>
<td>23</td>
<td>1.57</td>
<td>17</td>
<td>2.18</td>
<td>11</td>
</tr>
<tr>
<td>6 months HIV positive</td>
<td>20</td>
<td>0.78</td>
<td>17</td>
<td>0.97</td>
<td>11</td>
</tr>
<tr>
<td>6 months HIV negative</td>
<td>12</td>
<td>1.71</td>
<td>11</td>
<td>2.20</td>
<td>8</td>
</tr>
<tr>
<td>12 months HIV positive</td>
<td>11</td>
<td>1.57</td>
<td>8</td>
<td>0.97</td>
<td>8</td>
</tr>
<tr>
<td>12 months HIV negative</td>
<td>8</td>
<td>0.78</td>
<td>6</td>
<td>0.33</td>
<td>5</td>
</tr>
</tbody>
</table>

Is it time to rethink the roles of health professionals in the HIV outpatient setting?

HIV outpatient services across the United Kingdom are seeing large increases in their patient workload. This is fuelled by the success of highly active antiretroviral therapy (HAART), resulting in fewer deaths, and by increases in the number of new diagnoses. A further rise is anticipated in England following implementation of “The national strategy for sexual health and HIV” plans that to increase HIV testing dramatically in order to reduce the number of undiagnosed HIV infections by 50% by the end of 2007. The success of HAART has also changed the focus of many doctors’ patient outcomes. Serological response to treatment of syphilis in patients with HIV infection. Arch Intern Med 1996; 156: 321–5.

References

Contributors
SE and DM developed the study; SE, SD, and CG collected and analysed the data; SD and KM wrote the text. SE, DM, and CG provided comments on the text.

S S Dave
Matrimon Market Centre, Camden Primary Care Trust, London WC1E 6AU, UK
K Miles, S Griffiths, D E Mercey
Department of Sexually Transmitted Diseases, Royal Free and University College Medical School, University College London, UK
S G Edwards
Matrimon Market Centre, Camden Primary Care Trust, London WC1E 6AU, UK
Correspondence to: Dr Sangeta S Dave, Matrimon Market Centre, Camden Primary Care Trust, London WC1E 6AU, UK; sangeta.dave@camdenpct.nhs.uk
Funding: None.
Competing interests: None declared.
Reference

4. Wei R, Fishman D. Syphilis: have we dropped the ball? CMAJ 2002;167:1267–8

Online HIV/STI Chinese clinician training

The spread of HIV in China is accelerating and many Chinese physicians are poorly trained to address it. We review clinician training and the internet in China, and present the results of a convenience sampling of 136 Chinese clinicians regarding their access and attitudes towards computer based HIV/STI training.

Having been trained in an era of virtual STI eradication, many Chinese physicians are inadequately prepared to respond to the current HIV epidemic. Chinese medical school curricula frequently lack STI coursework, and a European Union-China Project (EUCP) study in 2000 showed as few as 5% of physicians had ever received any HIV/STI training. Coinciding with the spread of HIV in China is the exponential growth of the internet and computer technology, reaching over 68 million internet users as of June 2003. These computer based resources can potentially serve as a powerful medium for the training of clinicians.

To investigate this opportunity, we adapted Chinese language HIV/STI materials developed by the EUCP to create an online HIV/STI training page for the website of the Chinese National AIDS Prevention and Control Center (www.aids.net.cn). We then presented the site and distributed printed based surveys to 136 clinicians recruited during STI training courses in several urban areas.

The response rate was 97% (132/136). Among those sampled, 95% reported having computer access and 86% reported having internet access, defined as access at home, work, or internet cafes. Similar access levels were reported by the subset of respondents (17%) who reported having had no HIV/AIDS training in medical school or in continuing medical education (CME). All 132 respondents reported a willingness to utilise computer based training.

This study found a surprisingly high level of computer and internet access among a convenience sample of STI specialists from several urban areas in China. The main limitation of this study was the non-representative sampling, which makes generalisation to other Chinese physicians difficult. Despite this, we believe that these results can be cautiously applied to significant numbers of urban Chinese clinicians who share similar levels of access and interest with this study population.

Online CME presents a promising way to take advantage of growing computer/internet access in China. Chinese physicians can already obtain many of their required CME credits online, with the China Medical Education Center (www.cmechina.net) training over 50,000 users annually. Notably, HIV/AIDS training is not available.

Other potential uses of computer/internet resources include creating training centres to serve as clearing houses for up to date training materials. Especially in those areas where extreme geographic barriers limit the scope of traditional training methods, the internet can help remote hospitals and physicians engage in distance learning.

As China strives to control a growing HIV epidemic with a limited budget, low cost/high output resources like computer/internet training cannot be overlooked. While further investigation is needed to show training efforts positively affect outcomes, the computer/internet revolution offers an immediate and cost effective opportunity to train many urban and some rural physicians. This study suggests that the technical access and clinician willingness necessary for such HIV/STI training may already exist.

J D Tucker, C Jia, G E Henderson, M S Cohen University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

J A Davis University of California at San Francisco, San Francisco, CA, USA

X C Wang Chinese Centers for Disease Control, Beijing, China

Correspondence to: Joseph D Tucker, UNC School of Medicine, University of North Carolina at Chapel Hill, Mailbox 346, CB 7000, Chapel Hill, NC 27599-7000, USA; Joseph_Tucker@med.unc.edu

Accepted for publication 18 September 2003

References


Treatment of vulval vestibulitis with a potent topical steroid

Vulval vestibulitis (vestibulodynia) is characterised by penetrative introital pain and erythema and tenderness localised to the vestibular glands. The aetiology is unknown and most treatment strategies are based on anecdote. Some clinicians recommend the use of a topical steroid but there are no published data to support this.

We designed a randomised double blind crossover study to compare a potent topical steroid, Dermovate ointment (clobetasol propionate 0.05%), with a very mild steroid, 0.3% hydrocortisone ointment. The hydrocortisone acted as a placebo as it was impossible to obtain a matching placebo for Dermovate ointment. To demonstrate a 20% difference...
between Dermovate and hydrocortisone treated episodes if the placebo effect was 40%, 110 patients were needed. Unfortunately, recruitment was slow and the study ended when the expiry date of the medications was reached.

This report describes the outcomes in the patients who participated. The ethics committee of Mount Vernon and Watford Hospitals NHS Trust approved the study; patients gave written informed consent. All patients had intrafollicle pain, tenderness, and erythema compatible with a diagnosis of vulval vestibulitis. The study comprised three phases:

1. emollients only for 2–8 weeks,
2. tube one of the study medication, applied to the vestibule each night for 28 nights,
3. tube two of medication used similarly.

The tubes were identical and the study was designed so that within blocks of 10 patients, half would use each medication first. The same clinician assessed each patient at 14 days intervals using a three point scale for each of the parameters—pain, tenderness, and erythema (maximum score 9; minimum score 0 for each visit). The scores obtained at entry (minimum 3) and after each phase were noted.

Twenty two patients were recruited, but some patients withdrew or were excluded for protocol violations. Fourteen patients completed all phases of the study and two completed the first two phases. After emollient use, nine patients had improved (mean score −1.1; range −0.5 to −2); after Dermovate, 11 improved (mean score −2.7; ranges −0.5 to −8); and after hydrocortisone nine improved (mean score −1.8; range −1 to −3) (table 1). Eight patients who used both treatments had a better response to Dermovate and four had a better response to hydrocortisone (p = 0.07). Eight patients expressed a definite preference, seven for Dermovate and one for hydrocortisone. There may, however, have been an effect of the order of the treatments as two patients did better on their first treatment whereas nine did better on their second (p = 0.06).

Although this study was not completed, some conclusions can be reached. Short term use of a potent topical steroid preparation did not produce a clinically important improvement in all cases but some patients had very good responses, which were maintained. This may reflect the fact that the aetiology of vulval vestibulitis is multifactorial and where there has been an inflammatory, infective, or irritant cause, topical steroids may be helpful. There is an urgent need to identify and classify the causes of this syndrome so that appropriate treatment can be targeted more accurately.

Acknowledgements
I wish to thank Glaxo-Welcomes (now Glaxo-Smith Kline) for the supply of the study medication.

<table>
<thead>
<tr>
<th></th>
<th>Jarodove ointment</th>
<th>Hydrocortisone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Improved</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td>Unchanged</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Worse</td>
<td>2</td>
<td>5</td>
</tr>
</tbody>
</table>

P E Munday
Watford Sexual Health Centre, Watford General Hospital, Vicarage Road, Watford, WD18 0HB, UK; pat.munday@whstl.nhs.uk

doi: 10.1136/sti.2003.007328

Accepted for publication 6 December 2003

References

Unexpected resistance in an African immigrant: lessons for the unwary
The number of people emigrating from Africa to the United Kingdom has been escalating. They contribute to the increasing number of heterosexuals with HIV in the United Kingdom. Increasingly, developing countries are improving their access to antiretroviral drugs through global funds for AIDS and other sources. It is well known that resistance to antiretrovirals develops where therapy is suboptimal or adherence is imperfect, and that such resistance is associated with poor outcome.

A Zimbabwean man aged 47 was admitted to the Royal Sussex County Hospital, in August 2001 with lobar pneumonia. He had excellent response to the appropriate antibiotics. He reported receiving treatment for tuberculosis twice in the past. He had a positive HIV antibody test which was done after pretest discussion. The baseline CD4 count and viral load were consistent with advanced infection, 20 × 10^9/1 (2%) and 134,000, respectively.

He was commenced on combination antiretroviral therapy with combivir and efavirenz, and had a good initial virological response with a drop of his viral load to 1230 (3.09 logs) in 2 weeks. However, his viral load rebounded to 71,000 at 6 weeks. He was thought to be non-adherent to the antiretrovirals at this stage and was questioned extensively regarding adherence. He claimed 100% adherence to his medication and denied any missed or late doses. Interactions with prescribed and non-prescribed medications were excluded.

At this stage a genotypic resistance test was organised from the sample, with a viral load of 71,000 and he was admitted to the local respite unit (The Sussex Beacons) for directly observed therapy (DOT). The viral load after 2 weeks of DOT was 240,000.

A genotypic resistance test revealed the following mutations: K65R, D67N, K70R, K103N, M184V, G190A, T215F, K219Q, suggesting that he had extensive resistance to nucleoside analogues and to all non-nucleosides. When he was reviewed with this resistance test result, he subsequendy knowledge of HIV testing or treatment in Zimbabwe, but identified combivir tablets as part of his anti-tuberculosis medication. Genotypic resistance testing of his archived sample before his commencement of treatment showed: M41L, V118I, M184V, T215F. He was then commenced on a salvage regimen of didanosine, tenofovir, kaletra, and saquinavir HG and had a good virological response with a viral load drop of 1350 (3.13 logs) in 4 weeks.

It remains uncertain whether in this case the individual had been aware of his HIV status. It is possible that antiretroviral medications may have been included as part of an unorthodox anti-tuberculosis regimen, given the high co-infection rate in Zimbabwe, without the individual having been informed. Alternatively, the individual may have been unwilling to disclose his status for fear of rejection of his legal claim to stay in the United Kingdom or for other sociocultural reasons.

Either way, the choice of initial therapy was inappropriate, given the underlying resistance to reverse transcriptase analogues, and resulted in the subsequent rapid accumulation of NNRTI resistance.

While it is known that acquired resistance mutations may disappear with time after discontinuation of therapy, a genotypic resistance test was performed at presentation in this case a more effective regimen would have been selected. Current BHIVA guidelines recommend resistance testing before therapy only in the context of demonstrable transmitted drug resistance.

As antiretroviral therapies become increasingly available in developing countries and while stigma regarding disclosure of HIV status for immigrants remains, we believe that similar cases will occur.

We strongly suggest that immigrants with a new HIV diagnosis should be closely questioned regarding previous treatment and, and also baseline resistance testing should be routinely considered.

U R Natarajan, M Fisher
Brighton and Sussex University Hospitals NHS Trust, Brighton, UK

Correspondence to: U R Natarajan, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK; ushawrite@bt.com

doi: 10.1136/sti.2003.007542

Accepted for publication 3 November 2003

References
Increased uptake of HIV screening following introduction of ‘opt out’ testing and results by telephone

Rogstad et al showed an increase both in the number of patients who were offered the HIV test and those who took the test following the use of a leaflet. We report the increased uptake rate of HIV testing since the introduction of ‘opt out’ testing and giving results by phone.

Before January 2002, patients attending our clinic were offered an HIV test if they belonged to high risk groups such as men who have sex with men or injecting drug users. Pretest counselling was done by our health advisers and patients were required to return to the clinic to receive their test results. In 2001, 904 of 2930 new and re-registered patients (31%) underwent HIV testing.

The UK government’s national strategy for sexual health and HIV set its target for reducing undiagnosed HIV in genitourinary medicine clinics by increasing the uptake of HIV testing to 40% by the end of 2004 and to 60% by the end of 2007.

From January 2002, we introduced an “opt out” system, whereby all patients were offered HIV tests, regardless of risk category. This led to an increase in HIV test uptake in the following 3 months to 37% (272 of 740 new patients).

This caused an increase in the workload of our health advisers, who were spending much time in pretest counselling low risk patients and giving negative HIV results. It became clear that exhaustive, in-depth pretest counselling was impractical and inappropriate when the majority of those tested were “low risk.” Accordingly, we decided that only high risk patients should be referred pretest to the health advisers.

It was also observed that some patients who initially agreed to undergo HIV testing changed their minds when they learned that they would be required to return to the clinic to collect their result. We decided to offer HIV results by telephone, in line with our policy for all other screening tests. High risk patients, however, were encouraged to attend in person for their result. In the next 3 months 44% (327 of 740 new patients) took HIV tests.

Five patients tested HIV positive, but only one received the result by telephone.

The introduction of a telephone HIV results system enabled us to exceed the Department of Health target for 2004. The new system was adopted after consideration of the pros and cons in a departmental meeting in which the opinions of all staff were canvassed. Some concern was expressed about the potential for high risk patients given bad news outside the clinical setting. We tried to minimize such outcomes by encouraging patients to telephone in the presence of their partner, a friend, or a relative. Results were only given by telephone when the patient could be seen in clinic on the following day at the latest.

The telephone results system is very popular. One patient said, he would far rather receive bad news in the familiar surroundings of home, with the support of his partner, than in a clinic. Why? It is psychologically less harmful (or indeed beneficial) for patients to receive a positive HIV result by telephone; research is needed to answer this question. Given the drive to reduce the number of postponed HIV infections and the demands of working life, we believe telephone results are here to stay.

M Mahto, S P Higgins
Department of GU Medicine, North Manchester General Hospital, Manchester M8 8RB, UK

Correspondence to: Dr M Mahto, Genitourinary Medicine Department, Stepping Hill Hospital, Stockport, SK2 7JE, UK, dmatho@onetel.net.uk

Accepted for publication 8 October 2003

References

8th European Society of Contraception Congress

The 8th European Society of Contraception Congress will be held from 23–26 June 2004 in Edinburgh, Scotland, UK. For further details please contact ESC Central Office, c/o Orga-Med Congress Office, Essenerstraat 77, B-1740 Ternat, Belgium (tel: +32 2 582 08 52; fax: +32 2 582 55 15; email: organa@pandora.be; and website: http://www.contraception-esc.com/edinburgh.htm).

CORRECTION


The statistical calculation of this table combined all women, regardless of age. The authors have recalculated this table, and the revised version is available on the website (http://sti.bmjournals.com/cgi/data/79/1/22/DC1/1) with the correct age restriction — female participants 16 to 24 years only, as originally specified. The majority of these data (general practice, family planning, and youth clinics) have only changed marginally; the main differences lie within the GUM clinics, due to the wider age of women tested at this setting. The conclusions, however, are unaffected by this error. The authors stand by their assertion that prevalence tends to be higher in those reporting and attending with symptoms than those screened opportunistically.

CD-ROM REVIEW

Topics in International Health: Sexually Transmitted Infections, 2nd ed

Institutional licence £120; individual licence £30; developing world licence £20. CD-Roms are not Apple Mac compatible. Disc adviser: Dr J E Richens, Department of Sexually Transmitted Diseases, Royal Free and University College London Medical School, UK. London: The Wellcome Trust, 2003. ISBN 0 85199 631 0.

Having previously resisted the temptation to upgrade from printed text to the 21st century I was suitably impressed by both the technical design and the factual content of this 2nd edition CD-Rom. As a bit of a computer novice I found the software easy to install and navigate with helpful instructions at the touch of a button. The program itself runs on Windows 95, 98, 2000, NT4, or XP and needs 32MB of RAM with at least a 120 MHz Intel Pentium processor (or equivalent).

The CD-Rom provides a vast wealth of information on all aspects of common and tropical STIs that are presented in the form of 18 interactive tutorials, each reviewed by expert authors, and a collection of about 800 images. The material covers a wide range of epidemiological synergy with common STIs and their material includes an excellent overview of all the tutorials appear chronologically in the image collection and can be printed. They can also be sorted and saved in groups of your choice. The only hitch is that they can’t be downloaded into presentations, personal slide libraries, or palm pilots—shame!

The detail presented is still not enough to rival textbooks such as King Holmes’s Sexually Transmitted Diseases but this is not the purpose of the CD-Rom. It is ambitiously designed for use as an educational resource in both developed and developing countries and I think it serves this purpose well. Its appeal spans a broad range: medical students swatting for exams (and small-sitting Dip GUM) academic researchers as a useful point of reference and all healthcare professionals involved in direct clinical care of patients with STIs including nurses and health advisers.

Overall, the CD-Rom provides an interactive way of accessing and assimilating a huge amount of information on all aspects of STIs. It is definitely much more user friendly than lugging a huge textbook around and gets a big thumbs-up from me!